Project Grant HT94252410328
Award Date 5/1/24
Completion Date 4/30/27
Dollars Obligated $440K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada
Similar Awards
- This Project Grant award of $508,747.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), supports the "THE OVARIAN CANCER OBSERVATORY: PREVENTION, IMPACT, AND LEARNING FROM OPPORTUNISTIC SALPINGECTOMY" research project conducted by the Provincial Health Services Authority (operating as BC Cancer) in Canada. Through this multi-year (Sep 1, 2023 - Aug 31, 2027) grant, BC Cancer will perform biomedical research to develop...
- The federal Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $807,400.00 to the Provincial Health Services Authority (BC Cancer) in Canada. The grant, awarded on May 1, 2024, supports a research project titled "DECODING HOW DISTINCT MECHANISMS OF GENOMIC INSTABILITY FOUND IN TNBC PATIENTS PROGRAM THE TISSUE MICROENVIRONMENT AND THERAPY RESPONSE AT METASTATIC SITES." This project aims to investigate...
- The U.S. Defense Health Agency awarded a $907,170 Project Grant to the Provincial Health Services Authority (operating as BC Cancer) in Canada. This grant, provided under the Department of Defense's Military Medical Research and Development program (CFDA 12.420), supports research on therapeutic targeting of genomic instability in triple-negative breast cancer. The 3-year project, running from September 2023 to September 2026, aims to advance the understanding and treatment of this aggressive...
- The U.S. Defense Health Agency awarded a $109,895 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Provincial Health Services Authority (operating as BC Cancer) in Canada. The grant is for the purpose of "DEVELOPING FIRST-IN-KIND PRECLINICAL MODELS OF PRIMARY TESTICULAR LYMPHOMA" over a 2-year period from September 1, 2024 to August 31, 2026. As a prominent Canadian healthcare organization specializing in cancer research, treatment, and...
- Federal Project Grant Award Summary The University of British Columbia received a $426,154 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025, through August 31, 2027. The grant supports research investigating ASCL1-driven immunological landscapes in neuroendocrine prostate cancer, with the objective of enhancing immunotherapy efficacy. This research falls within the DHA's broader mission to...
- The federal Project Grant award of $1,477,615.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will fund comparative transcriptomic and proteomic profiling of full-length androgen receptor (AR) and AR-V7 splice variant condensates in prostate cancer at the University of British Columbia. The research, to be conducted from April 15, 2025 to April 14, 2028, aims to transform healthcare for military service members, veterans, and the broader public...
- This Project Grant award for $1,126,685 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports translatome profiling research conducted by the University of British Columbia (UBC) to identify biomarkers and therapeutic targets for prostate cancer. The project aims to leverage UBC's expertise in biomedical research and advanced analytical capabilities to advance the understanding and treatment of prostate cancer, which is an...
- The federal Project Grant award in the amount of $499,999.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), funds research by the Institute of Cancer Research: Royal Cancer Hospital (The) to study the interplay of molecular and spatial architectures with clinical states in prostate cancer. The research project aims to make discoveries that defeat cancer through innovative biomedical research. As a subawardee, the Institute of...
- The federal Project Grant award of $1,578,836.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) in developing and exploiting a third-generation prostate cancer dependency map to identify cancer vulnerabilities and treatment targets. The award, which runs from August 1, 2024 to July 31, 2027, will enable the research organization to conduct innovative...
- The Department of the Army Medical Command awarded a $990,000 project grant to the Provincial Health Services Authority in Canada to support research on mechanisms and therapeutic strategies for overcoming MNA-mediated immune suppression in ovarian cancer. The grant was awarded under the Military Medical Research and Development program (CFDA 12.420), which aims to transform health care for service members and the public through innovative biomedical research solutions for battlefield...